Segment Information - Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Net sales	$ 14,681	$ 3,935
Cost Of Revenue	1,640	2,003
Direct expenses	19,871	54,670
Segment contribution	(6,830)	(52,738)
Indirect expenses	546	11,132
Loss from operations	(7,376)	(63,870)
Components of other
Change in fair value of contingent consideration liability	0	(18,932)
Change in fair value of contingent stock consideration		(110)
Goodwill impairment	0	29,633
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	5,465	40,162
Segment contribution	(5,465)	(40,162)
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,287	1,357
Cost Of Revenue	177	472
Direct expenses	416	344
Segment contribution	694	541
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	13,394	2,578
Cost Of Revenue	1,463	1,531
Direct expenses	4,414	3,009
Segment contribution	7,517	(1,962)
Other
Segment Reporting Information [Line Items]
Direct expenses	9,576	11,155
Segment contribution	(9,576)	(11,155)
Indirect expenses	546	11,132
Components of other
Change in fair value of contingent consideration liability		(18,932)
Change in fair value of contingent stock consideration		(110)
Goodwill impairment		29,633
Amortization	546	541
Total other	$ 546	$ 11,132